Professional Documents
Culture Documents
The Mu Opioid Receptor: A New Target For Cancer Therapy?
The Mu Opioid Receptor: A New Target For Cancer Therapy?
Mu opioids are among the most widely used drugs for patients with cancer with both acute and chronic pain as well as in the perioperative period. Several retrospective studies have suggested that opioid use might promote tumor progression and as a result negatively
impact survival in patients with advanced cancer; however, in the absence of appropriate prospective validation, any changes in recommendations for opioid use are not warranted. In this review, the authors present preclinical and clinical data that support their hypothesis
that the mu opioid receptor is a potential target for cancer therapy because of its plausible role in tumor progression. The authors also
propose the hypothesis that peripheral opioid antagonists such as methylnaltrexone, which reverses the peripheral effects of mu opioids
but maintains centrally mediated analgesia and is approved by the US Food and Drug Administration for the treatment of opioidC 2015 American Cancer Society.
induced constipation, can be used to target the mu opioid receptor. Cancer 2015;121:2681-8. V
KEYWORDS: cancer progression, methylnaltrexone, mu opioid receptor, opioids.
INTRODUCTION
Mu opioids are among the most widely used drugs for patients with cancer with both acute and chronic pain as well as during the perioperative period.1 Although there exists a family of opioid receptors (mu, kappa, delta, and nociception/orphanin FQ peptide), the G protein-coupled mu opioid receptor (MOR) is the therapeutic target for most clinically used
opioids, including morphine and fentanyl.2 The choice of anesthetic and its influence on cancer progression and outcome
has been extensively studied within the perioperative setting and there is increasing awareness by anesthesiologists of the
value of opioid-sparing techniques.3-7 Over the past decade, there has been evolving literature suggesting a relationship
between the MOR and cancer progression and recurrence extending to the management of chronic cancer pain. Preclinical data from several laboratories have suggested that mu opioids can promote cancer progression,8-10 but to the best of
our knowledge prospective human studies have been limited. The development and approval of methylnaltrexone
(MNTX), a peripherally restricted MOR antagonist, has allowed clinical studies to progress in this area.11 MNTX was
approved by the US Food and Drug Administration in 2008 to treat opioid-induced constipation (OIC) in patients with
advanced illness who are receiving palliative care and in whom response to laxatives is insufficient, and more recently to
treat OIC in patients with chronic nonmalignant pain. Because MNTX reverses the peripheral effects of mu opioids but
maintains centrally mediated analgesia, it can be given to patients receiving opioids. MNTX can be used to separate out
the peripheral from central effects of opioids both in the laboratory and in the clinical setting. Although to our knowledge
there are few preclinical studies demonstrating an effect of peripheral opiate antagonists on analgesia, clinical studies
regarding the approved agents naloxegol, alvimopan, and methylnaltrexone at normal therapeutic doses have not shown
an adverse effect on pain control or increased opioid use among patients with acute or chronic pain.
There are significant differences between the perioperative setting, in which opiate-naive individuals often are
exposed to high doses of opiates within a limited time frame, and chronic cancer, in which nearly one-half of patients
receive opiates for considerable periods of time.1 Aside from the differences in clinical time of exposure to mu opiates, it is
important to distinguish the effects of the MOR on tumorigenesis versus effects on tumor growth and metastasis. Very
recently, the relationship between opioid use and cancer progression has been demonstrated in patients with advanced
prostate cancer.12 Although there has yet to be any convincing prospective studies that would mandate a change in
Corresponding author: Filip Janku, MD, PhD, Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Box 0455, Houston, TX 77030; Fax: (713) 745-2374; fjanku@mdanderson.org.
1
Section of Pulmonary and Critical Care, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois; 2Department of Anesthesia and Critical Care, The University of Chicago, Chicago, Illinois; 3Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; 4Clinical Translational Research Center, The University of Texas MD Anderson Cancer Center, Houston,
Texas
DOI: 10.1002/cncr.29460, Received: February 11, 2015; Revised: April 3, 2015; Accepted: April 8, 2015, Published online June 4, 2015 in Wiley Online Library
(wileyonlinelibrary.com)
Cancer
2681
Review Article
Figure 2. Graphic analysis of Lewis lung carcinoma tumor volume in wild-type and mu opioid receptor (MOR) knockout
mice (5 animals per condition; P<.001). C57BL/6 wild-type
and MOR knockout mice (MOR-/-) were injected with dualcolor labeled Lewis lung carcinoma cells (1 3 106) subcutaneously in the right flank. Adapted from Biji M, Lennon F, Siegler J, et al. The novel role of the mu opioid receptor in lung
cancer progression: a laboratory investigation. Anesth Analg.
2011;112:3.25
Cancer
2683
Review Article
TABLE 1. Preclinical Studies Involving the MOR and Cancer
Effects of Mu Opioids on Tumor Growth and Metastasis
1
2
Techniques
Findings
Abbreviations: LLC, Lewis lung carcinoma; LPS, lipopolysaccharide; MNTX, methylnaltrexone; MOR, mu-opioid receptor, mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.
Figure 4. Increased mu opioid receptor (MOR) expression in patients with metastatic lung cancer. Paraffin-embedded archived
biopsy samples from patients with non-small cell lung cancer were stained using MOR antibody and scored qualitatively by 2 independent pathologists using a 4-point scale. In human lung cancer and normal adjacent lung samples obtained from 34 patients
with lung cancer, MOR expression was found to be significantly increased in samples from patients with lung cancer compared
with adjacent control tissue (P =.0242). When the samples from patients with metastatic lung cancer were separated from those
of the cohort of the total number of patients with lung cancer, an approximately 2-fold increase in MOR expression was observed
(P =.0013). Adapted from Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased mu-opioid receptor expression in
metastatic lung cancer. Br J Anaesthes. 2014;113(suppl 1):i103-i108.46
observed in a Chinese study with 260 patients with esophageal squamous cell cancer and 291 controls. The patients
were overrepresented by wild-type MOR, whereas those
with A118G homozygotes had significantly less cancer on
multivariate analysis (odds ratio, 3.12; P 5 .001).42
Finally, as previously mentioned, increased b-endorphin
expression in human melanoma was correlated with
shorter progression-free survival (PFS).34
To our knowledge, there are limited populationbased data regarding whether opioids themselves can precipitate malignancy or influence tumor progression.7,43,44
A retrospective study examining 700 patients and 4000
patient-years compared the influence of methadone maintenance therapy versus chronic naltrexone therapy and
demonstrated no difference in the incidence of cancers45;
however, there were only 5 cancers diagnosed in the entire
patient population, suggesting that this study was underpowered to answer that question.
Another approach has been to examine MOR
expression in tumors. Several laboratories have demonstrated that the MOR is overexpressed in both malignant
lung and prostate tissue.12,46,47 In a small study of 34
patients with NSCLC, samples of adjacent nonmalignant
tissue revealed lower MOR expression on immunohistochemistry compared with tumor samples (P =.02). Furthermore, tumor samples from patients with lymph node
metastases had the highest MOR expression (P =.001)
(Fig. 4).46 A similar observation was reported from a study
with 480 patients with advanced prostate cancer, in which
greater opioid requirements were associated with shorter
PFS (hazard ratio [HR], 1.08; P<.001) and overall survival (OS) (HR, 1.07; P<.001).12 Of special clinical interest, every 5-mg/day increment in the opioid
requirement increased the risk of disease progression by
2685
Review Article
TABLE 2. Clinical Studies Involving the MOR and Cancer
The Mu Opioid Receptor and Cancer Progression
No. of Patients
Techniques
Findings
2039
9385
551
593
34
239
4329
202
129
247
47,000
901
99
Abbreviations: CMM, comprehensive medical management; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; EA, epidural anesthesia;
GA, general anesthesia; IDDS, intrathecal drug delivery systems; LLC, Lewis lung cancer; MOR, mu-opioid receptor; NSCLC, non-small cell lung cancer; OS,
overall survival; PFS, progression-free survival.
whether the patient received a combined general anesthetic with paravertebral block or a general anesthetic that
included opioids (94% vs 77%; P 5 .012).48 Similarly, a
retrospective study of 225 patients with early-stage prostate cancer undergoing radical prostatectomy demonstrated that an epidural plus general anesthesia compared
with general anesthesia with opioids was associated with a
lower risk of disease recurrence (HR, 0.43; P 5 .012).12 A
recent meta-analysis summarized a large number of studies in the anesthesia literature addressing the issue of anesthetic technique and cancer.49 The results of this metaanalysis suggested that epidural anesthesia and/or
Cancer
There is emerging evidence that MOR expression and signaling plausibly plays a role in cancer progression by interacting
with angiogenesis, EMT, mTOR, Src, and other signaling
pathways. These findings have been substantiated by retrospective data suggesting worse outcomes in patients with cancer who are exposed to systemic opioids or those with high
levels of MOR expression. MNTX is a peripherally acting
MOR antagonist that is used for the treatment of refractory
OIC. Preclinical data have suggested that MOR inhibition
can reverse the adverse effect of MOR signaling on cancer
progression and further investigation in the clinical setting is
warranted. The first dose-finding study, which combines
MNTX with chemotherapy, is currently under way.
FUNDING SUPPORT
No specific funding was disclosed.
REFERENCES
1. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A longterm survey of morphine in cancer pain patients. J Pain Symptom
Manage. 1992;7:259-266.
Cancer
2. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR. Challenges for
opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol.
2015;172:317-323.
3. Bovill JG. Surgery for cancer: does anesthesia matter? Anesth Analg.
2010;110:1524-1526.
4. Snyder GL, Greenberg S. Effect of anaesthetic technique and other
perioperative factors on cancer recurrence. Br J Anaesth. 2010;105:
106-115.
5. Yeager MP, Rosenkranz KM. Cancer recurrence after surgery: a role
for regional anesthesia? Reg Anesth Pain Med. 2010;35:483-484.
6. Lennon FE, Moss J, Singleton PA. The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012;116:940945.
7. Buggy DJ, Borgeat A, Cata J, et al. Consensus statement from the
BJA Workshop on Cancer and Anaesthesia. Br J Anaesthes. 2015;
114:2-3.
8. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling
and promotes breast tumor growth. Cancer Res. 2002;62:4491-4498.
9. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of
receptor transactivation. Microvasc Res. 2006;72:3-11.
10. Leo S, Nuydens R, Meert TF. Opioid-induced proliferation of vascular endothelial cells. J Pain Res. 2009;2:59-66.
11. Moss J, Rosow CE. Development of peripheral opioid antagonists
new insights into opioid effects. Mayo Clin Proc. 2008;83:11161130.
12. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced
prostate cancer. Cancer. 2013;119:4103-4110.
13. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J,
Singleton PA. Overexpression of the mu-opioid receptor in human
non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012;116:857-867.
14. Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu
opioid receptor in lung cancer progression: a laboratory investigation. Anesthes Analg. 2011;112:558-567.
15. Zagon IS, McLaughlin PJ. Opioid antagonists inhibit the growth of
metastatic murine neuroblastoma. Cancer Lett. 1983;21:89-94.
16. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in
mice with neuroblastoma. Science. 1983;221:671-673.
17. Singleton PA, Garcia JG, Moss J. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther.
2008;7:1669-1679.
18. Singleton PA, Mambetsariev N, Lennon FE, et al. Methylnaltrexone
potentiates the anti-angiogenic effects of mTOR inhibitors.
J Angiogenes Res. 2010;2:5.
19. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL,
Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir
Cell Mol Biol. 2007;37:222-231.
20. Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG. Epithelial to
mesenchymal transition: the doorway to metastasis in human lung
cancers. J Thorac Cardiovasc Surg. 2010;140:505-513.
21. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal
transition in cancer development and its clinical significance. Cancer
Sci. 2010;101:293-299.
22. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
23. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer
metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75-90.
24. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The Mu
opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in
human lung cancer. PLoS One. 2014;9:e91577.
25. Biji M, Lennon F, Siegler J, et al. The novel role of the mu opioid
receptor in lung cancer progression: a laboratory investigation. Anesthes Analg. 2011;112:3.
2687
Review Article
26. Pelleitier M, Montplaisir S. The nude mouse: a model of deficient
T-cell function. Methods Achieve Exp Pathol. 1975;7:149-166.
27. Welden B, Gates G, Mallari R, Garrett N. Effects of anesthetics and
analgesics on natural killer cell activity. AANA J. 2009;77:287-292.
28. Munoz M, Rosso M, Casinello F, Covenas R. Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res Treat.
2010;122:601-603.
29. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, BenEliyahu S. Attenuation of the tumor-promoting effect of surgery by
spinal blockade in rats. Anesthesiology. 2001;94:1066-1073.
30. Wada H, Seki S, Takahashi T, et al. Combined spinal and general
anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology. 2007;106:499-506.
31. Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner
G, Garbe C. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res.
2000;10:165-169.
32. Christopherson R, James KE, Tableman M, Marshall P, Johnson
FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008;107:325-332.
33. McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid
growth factor ([Met]-enkephalin)-opioid growth factor receptor axis:
novel therapies for squamous cell carcinoma of the head and neck.
Head Neck. 2012;34:513-519.
34. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH,
Duthey B. Endogenous mu-opioid peptides modulate immune
response towards malignant melanoma. Exp Dermatol. 2011;20:2428.
35. Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic
mice with breast cancer. Br J Anaesth. 2014;113(suppl 1):i4-i13.
36. Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid
requirement and cancer pain with survival in advanced non-small
cell lung cancer [published online ahead of print October 10, 2014].
Br J Anaesth. pii: aeu351.
37. Forbes W, Patterson C; Salix Pharmaceuticals Inc. Relistor: Methylnaltrexone Bromide Subcutaneous Injection. Available at: http://
www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/
ucm401675.pdf. Accessed March 12, 2015.
2688
38. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an
implantable drug delivery system compared with comprehensive
medical management for refractory cancer pain: impact on pain,
drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040-4049.
39. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J.
2012;441:379-386.
40. Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and
opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013;14:813-824.
41. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H,
McLean SA. m-Opioid receptor gene A118G polymorphism predicts
survival in patients with breast cancer. Anesthesiology. 2012;116:896902.
42. Wang S, Li Y, Liu XD, Zhao CX, Yang KQ. Polymorphism of
A118G in m-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin
Oncol. 2013;18:666-669.
43. Maher DP, Wong W, White PF, et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesthes. 2014;113(suppl 1):
i88-i94.
44. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the
effect of intraoperative opioid dose on cancer recurrence after nonsmall cell lung cancer resection. Cancer Med. 2014;3:900-908.
45. Singleton PA, Moss J. Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010;6:1237-1242.
46. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J.
Increased mu-opioid receptor expression in metastatic lung cancer.
Br J Anaesthes. 2014;113(suppl 1):i103-i108.
47. Zhang YF, Xu QX, Liao LD, et al. Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous
cell carcinoma. Dis Esophagus. 2015;28:196-203.
48. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI.
Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105:660-664.
49. Chen WK, Miao CH. The effect of anesthetic technique on survival
in human cancers: a meta-analysis of retrospective and prospective
studies. PLoS One. 2013;8:e56540.
Cancer